Patient characteristics in the high vs. low pPI3K signaling CRC cohorts were well balanced in terms of their tumor stage, chemotherapy treatments, and mutational status of the oncogenes KRAS and BRAF (Fig. 2B). This evidence concerns the gene KRAS and colorectal carcinoma.